Jan Novák

机构：Charles University, University Hospital Kralovske Vinohrady · ORCID：0000-0003-1241-1635

发表论文 142 篇 · 总被引 4073 次 · h-index 31

代表论文

• The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy (2025 · Blood · 被引 57)
• Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy (2022 · Blood · 被引 39)
• Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy (2022 · Blood · 被引 39)
• Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 (2024 · EClinicalMedicine · 被引 34)
• Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial (2023 · Leukemia · 被引 31)
• Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study (2023 · Blood Advances · 被引 28)